Despite good data, Ironwood’s shares plummet
Ironwood Pharmaceuticals’ short bowel syndrome drug performed well in a Phase 3 trial, but the company’s shares still tanked 30%. What happened?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we’ll discuss how the U.S. government is cracking down on Chinese biotechs, and how that might affect the industry stateside. Also, a positive clinical trial for Ironwood Pharmaceuticals still causes a stock slump, and more.
What's Your Reaction?
